241 search results
- Current search:
- Blood disorders
- Reset
Primary tabs
- Cochrane Evidence (active tab)
- Resources
- Handbooks & Manuals
- Training & Workshops
- News
- All Cochrane sites
-
UpdatedCochrane EvidencePublished 7 Jul 2017
Statins for children with inherited high blood cholesterol
Review question We reviewed the evidence for the effectiveness and safety of statins in children with inherited high blood cholesterol. Background Familial hypercholesterolemia is an inherited disease in which the blood cholesterol level is high. Vascular disease, i.e. furring up of the blood vessels, often occurs at an earlier age than usual, especially ... -
UpdatedCochrane EvidencePublished 7 Jul 2017
Rituximab for treating inhibitors in people with inherited severe hemophilia
Review question We reviewed the evidence available to see if rituximab is effective and safe when treating clotting factor inhibitors in people with severe hemophilia. This is an update of a previously published Cochrane Review. Background Hemophilia A and B are inherited conditions in which there is either reduced levels (or none at all) of factor ... -
NewCochrane EvidencePublished 3 Jul 2017
Interventions to prevent or reduce kidney complications in people with sickle cell disease
Review question We wanted to determine if there were any safe and effective interventions that prevent or reduce kidney complications in people with sickle cell disease (SCD). Background SCD is a serious inherited blood disorder where the red blood cells, which carry oxygen around the body, develop abnormally. Normal red blood cells are flexible ... -
Cochrane EvidencePublished 25 May 2017
Comparison of the two international standards of chemotherapy for people with early unfavourable or advanced stage Hodgkin lymphoma
Review question For the treatment of early unfavourable and advanced stage Hodgkin lymphoma (HL) two different international standards are commonly used, either chemotherapy with escalated (intensified) BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) regimen or chemotherapy with ABVD (doxorubicin, ... -
Cochrane EvidencePublished 13 May 2017
Interventions to prevent silent strokes in people with sickle cell disease
Review question We wanted to determine if there were any safe and effective interventions that prevent silent strokes (also known as silent cerebral infarcts) in people with sickle cell disease (SCD). Background SCD is a serious inherited blood disorder where the red blood cells, which carry oxygen around the body, develop abnormally. Normal red ... -
Cochrane EvidencePublished 27 Apr 2017
Treatment of early stage Hodgkin lymphoma
Background Hodgkin lymphoma (HL) is a malignancy of the lymphatic system. It occurs in children and adults, but it is more common in the third decade of life. It is one of the most curable forms of cancer. There are four stages of HL, stages I and II are considered as early stage HL and stages III and IV as advanced stage. Using risk factors such ... -
Cochrane EvidencePublished 21 Apr 2017
Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients
Review question Is the incidence of heparin-induced thrombocytopenia lower in postoperative patients receiving thromboprophylaxis with low molecular weight heparin in comparison with patients receiving unfractionated heparin? Background Heparin is a natural agent used to prevent clot formation in the vessels. Two types of heparins are widely used, ... -
Cochrane EvidencePublished 20 Apr 2017
Hydroxyurea (also known as hydroxycarbamide) for people with sickle cell disease
Review question What is the effect of hydroxyurea on clinical outcomes (changes in pain crises, life-threatening illnesses, survival, haemoglobin levels, quality of life and side effects) in people with sickle cell disease (SCD) of any genotype? Background SCD is an inherited genetic disorder that creates problems with haemoglobin (the substance ... -
Cochrane EvidencePublished 16 Apr 2017
Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents (ESA) for cancer patients with anaemia: A systematic review and network meta-analysis
Protocol: The objectives are to systematically review the effect of intravenous iron or no iron in combination with erythropoiesis-stimulating agents (ESAs) on the prevention or alleviation of anaemic cancer patients and to generate a clinically meaningful treatment ranking according to their safety and efficacy. -
Cochrane EvidencePublished 14 Apr 2017
Magnesium for treating sickle cell disease
Review question We reviewed the evidence of the effect of intravenous (given into a vein) magnesium and oral (taken by mouth) magnesium on the frequency of painful crises (sickle cell crises with severe pain due to blockages of the blood supply to bones, joints, lungs, liver, spleen, kidney, eye or central nervous system), length of hospital stay ...
